The European Pharmacopoeia (Ph. Eur.) Monograph 0478 is the definitive general monograph governing the quality, production, and testing standards for Tablets within the European Union. Understanding this monograph is essential for pharmaceutical manufacturers to ensure batch-to-batch consistency and regulatory compliance. Core Requirements of Monograph 0478
The monograph establishes a strict framework for several categories of oral tablets, including uncoated, coated, gastro-resistant, and modified-release types.
Production Standards: Manufacturers must ensure that tablets are robust enough to withstand handling while maintaining precise delivery of the active substance. european pharmacopoeia ph eur monograph tablets 0478 better
Subdivision (Scored Tablets): If a tablet is designed to be broken, the "break-marks" must be functional. Ph. Eur. 0478 requires that subdivided parts meet specific uniformity of mass standards to prevent unpredictable dosing.
Uniformity of Content & Mass: Tablets with less than 2 mg of active substance or those making up less than 2% of total mass must comply with stringent "Uniformity of Content" tests to ensure each dose is accurate. Key Testing Protocols The European Pharmacopoeia (Ph
To achieve "better" compliance and product quality, manufacturers must adhere to these standardized tests: gmp-compliance.org Revised Ph. Eur. Chapter Tablets - gmp-compliance.org
The monograph emphasizes stability:
Monograph 0478 defines tablets as "solid preparations each containing a single dose of one or more active substances." They are obtained by compressing uniform volumes of particles or by other methods of manufacture (e.g., moulding).
A manufacturer using an old national standard might pass friability at 1.2% loss. Using Ph. Eur. 0478, that batch fails. The manufacturer must adjust compression force or binder concentration. The result? A better, more robust tablet that survives shipping from Spain to Sweden without crumbling. Containers: Must protect the tablets from light, moisture,
The monograph mandates that tablets must be robust enough to withstand handling, packaging, and transportation while releasing the active substance correctly upon administration.
Compare your existing specifications to Chapter 2.9.40 (Uniformity of Dosage Units) and 2.9.3 (Dissolution) referenced in 0478. Identify gaps in your dissolution apparatus calibration.